M&A / Deals Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact BioSpaceMerck will use Protillion Biosciences' tech to design biologic therapies for therapies across undisclosed indications.Read full story pharminent June 17, 2026 (Last updated: June 17, 2026) BioSpace Merck will use Protillion Biosciences’ tech to design biologic therapies for therapies across undisclosed indications. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Moderna builds commercial muscle as new launches loomNext: Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
